Company news
Trevi Therapeutics, Inc. (NASDAQ:TRVI) news
Trevi Therapeutics, Inc. news releases on 6ix. Latest, Aug 26, 2026: Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society…
Press releases & updates
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026
August 26, 2026
Trevi Therapeutics : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)
August 6, 2026
Trevi Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
August 6, 2026
Trevi Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026
July 30, 2026
Trevi Therapeutics Announces Upcoming June and July Event Schedule
June 17, 2026
Trevi Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
May 5, 2026
Trevi Therapeutics Announces Oral Presentation and Multiple Posters Accepted at the American Thoracic Society (ATS) 2026 International Conference
April 29, 2026
Trevi Therapeutics to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 5, 2026
April 28, 2026
Trevi Therapeutics to Participate in Upcoming May Events
April 23, 2026
Trevi Therapeutics Announces Closing of $173 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
April 20, 2026
Trevi Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
April 15, 2026
Trevi Therapeutics to Participate in Upcoming Events
March 31, 2026
Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates
March 16, 2026
Trevi Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results and Provide Business Updates on March 17, 2026
March 9, 2026
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough
March 8, 2026
Trevi Therapeutics to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 17, 2026
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
January 22, 2026
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
January 8, 2026
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
December 3, 2025
Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
November 12, 2025
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
November 5, 2025
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
November 3, 2025
Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting
October 7, 2025
Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025
September 17, 2025
Trevi Therapeutics to Participate in Upcoming September Conferences
August 27, 2025
Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 6, 2025
Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025
July 30, 2025
Trevi Therapeutics to Participate in Upcoming August Conferences
July 28, 2025
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism
June 30, 2025
Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
June 4, 2025
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
June 2, 2025
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
June 1, 2025
Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
June 1, 2025
Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
May 31, 2025
Trevi Therapeutics to Participate in Upcoming June Conferences
May 28, 2025
Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
May 19, 2025
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
May 7, 2025
Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025
April 30, 2025
Trevi Therapeutics to Participate in Upcoming April Investor Conferences
April 2, 2025
Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates
March 17, 2025
Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025
March 10, 2025
Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
March 9, 2025
Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
March 8, 2025
Trevi Therapeutics to Participate in Upcoming March Investor Conferences
February 26, 2025
Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
February 24, 2025
Trevi Therapeutics to Participate in Upcoming February Investor Conferences
January 29, 2025
Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
January 7, 2025
Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering
December 15, 2024
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
December 11, 2024
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine
December 2, 2024